These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33671892)

  • 1. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
    Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.
    Schalper KA; Carvajal-Hausdorf D; McLaughlin J; Altan M; Velcheti V; Gaule P; Sanmamed MF; Chen L; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Jan; 23(2):370-378. PubMed ID: 27440266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
    Mandarano M; Bellezza G; Belladonna ML; Van den Eynde BJ; Chiari R; Vannucci J; Mondanelli G; Ludovini V; Ferri I; Bianconi F; Del Sordo R; Cagini L; Albini E; Metro G; Puma F; Sidoni A
    Virchows Arch; 2019 Feb; 474(2):159-168. PubMed ID: 30448912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
    Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
    Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
    Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
    Okadome K; Baba Y; Nomoto D; Yagi T; Kalikawe R; Harada K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Shono T; Sasaki Y; Baba H
    Br J Cancer; 2020 May; 122(10):1535-1543. PubMed ID: 32210369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the immunoescape in colorectal cancer liver metastasis.
    Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
    Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
    Volaric A; Gentzler R; Hall R; Mehaffey JH; Stelow EB; Bullock TN; Martin LW; Mills AM
    Am J Surg Pathol; 2018 Sep; 42(9):1216-1223. PubMed ID: 29901571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
    Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
    Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.